成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> ACS Applied Energy Materials >>article
ACS Applied Energy Materials

ACS Applied Energy Materials

IF: 5.4
Download PDF

Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.

Published:1 November 2020 DOI: 10.1016/j.intimp.2020.106906 PMID: 33182057
Shradha Bodkhe, Mayuri Nikam, Atul P Sherje, Tabassum Khan, Vasanti Suvarna, Kavit Patel

Abstract

Phosphodiesterase-4 inhibitors (PDE4) are of great interest for the treatment of airway inflammatory diseases due to its broad anti-inflammatory effects. Roflumilast is a selective PDE4 inhibitor that inhibits pulmonary and systemic inflammation and rallies symptoms in airway diseases. Asthma and COPD are common chronic airway inflammatory diseases having incompletely illustrious pathophysiology and clinical manifestations. Recently, the condition called Asthma- COPD Overlap (ACO) has been evolved having the overlapping symptoms of both diseases. The newly discovered PDE4 inhibitor, roflumilast has exposed its potential in the treatment of Asthma, COPD and ACOS. Its mechanism of action in airway inflammatory diseases are said to be exerts by elevating intracellular cAMP and shows its anti-inflammatory action. Roflumilast, a promising therapeutic approach in inflammatory airway diseases, has many significant outcomes. In this review, we have provided various promising clinical evidences of roflumilast in COPD and asthma. However, there is no published clinical evidence to date for the role of roflumilast in ACOS. Nevertheless, there are therapeutic mechanisms that provide a reference for clinical application for ACOS.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Roflumilast 162401-32-3 C17H14Cl2F2N2O3 501 suppliers $5.00-$1789.00
PDE4 antibody 7 suppliers Inquiry

Similar articles

IF:5.4

Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap.

ACS Applied Energy Materials Xiaoli Zhang, Yuqing Chen,etc Published: 1 August 2018
IF:2.1

Efficacy and safety profile of roflumilast in a real-world experience.

Journal of thoracic disease Aykut Cilli, Halid Bal,etc Published: 1 April 2019
IF:4.3

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.

ACS Applied Electronic Materials Noemi Lois, Evie Gardner,etc Published: 14 July 2020